Revive Therapeutics (CSE: RVV, US: RVVTF) Official

Revive Therapeutics Strengthens Bucillamine IP Portfolio Revive Therapeutics expands its #Bucillamine IP with new North American patent filings for nerve agent exposure and a granted Canadian patent for infectious diseases. revivethera.com/2026/03/revive… $RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #ReviveTherapeutics #MedicalCountermeasures

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study bit.ly/3YEmRVE $RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #DRDC #ReviveTherapeutics #RVVTF #RVV #MedicalCountermeasures #LifeSciences #Therapeutics

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study bit.ly/3M00ve2 $RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #DRDC

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity bit.ly/4nm4Vu1 $RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #DRDC #Braininjury

Revive Therapeutics Advances with Next-Generation Bucillamine Development bit.ly/3Hl9oNf $RVV $RVVTF #Biotech #Research #HealthCare #Bucillamine #InfectiousDiseases #Pharmaceuticals #DrugDevelopment #FDA

@RobertKennedyJr Revive Therapeutics is advancing research on Bucillamine for Long COVID & nerve agent exposure—key public health and national security issues. 🧬 Long COVID: bit.ly/4kLdZql 🧪 Nerve Agent Study: bit.ly/3GRYRsz 📄 Fact Sheet: bit.ly/3T3WipT Open to collaboration or discussion. $RVV $RVVTF

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure bit.ly/3GRYRsz $RVV $RVVTF #Biotech #Research #HealthCare #NerveAgentTreatment #Pharma #FDA #HealthInnovation #LifeSciences #ClinicalTrials #MedTech #PublicHealth #BioResearch #NerveAgent #Bucillamine #MedicalBreakthrough

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment bit.ly/3G0XmaS $RVV $RVVTF #cancer #bucillaminne #Biotech #CancerResearch

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program bit.ly/4ltNeYL $RVV $RVVTF #DiagnaMed #Acquisition #Hydrogen #Neurology #Mental #ALS #FDA #Antioxidant #Inflammatory #Clinical #Biotechnology

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program bit.ly/41pfHW3 $RVV $RVVTF #DiagnaMed #Acquisition #Hydrogen #Neurology #Mental #ALS #FDA #Antioxidant #Inflammatory #Clinical #Biotechnology

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure bit.ly/3WcZ8ef $RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke bit.ly/3O1Momt $RVV $RVVTF #psilocybin #therapy #stroke #treatment #psychedelic #neuroprotection $NUMI $MDMA $CYBN $PHRM $MNMD

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure tinyurl.com/m7x7ytp5 $RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures bit.ly/4e91B0h $RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada #monkeypox

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections bit.ly/3Xn1NDl $RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #FDA #HealthCanada #monkeypox

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure bit.ly/3VReIeA $RVV $RVVTF #Bucillamine #InfectiousDiseases #MedicalCountermeasures #RareDisorders #NerveAgent #DRDC #DefenceRDC #PharmacologicalResearch #FDA #HealthCanada #Neuroprotection #GABAReceptors #Antioxidants #SeizurePrevention #TraumaticBrainInjury

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID bit.ly/4bXS4YL $RVV $RVVTF #Bucillamine #InfectiousDiseases #pharmaceuticals #LongCovid #FDA #clinicalstudy

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product bit.ly/3RjvtO6 $RVV $RVVTF #Bucillamine #InfectiousDiseases #pharmaceuticals #LongCovid #FDA #clinicalstudy